SELF-ORDERING OXYGEN CARRIER COMPOSITIONS

Description

BACKGROUND OF THE INVENTION FIELD OF THE INVENTION

[0001] The present invention relates to synthetic blood substitutes and / or oxygen carrier compositions and methods for making them.BACKGROUND

[0002] Patent publication No: US6284267B1 describes a structural class of amphiphilic molecules which incorporate a hydrophilic material or polymer attached to hydrophobic residues. All such amphiphilic molecules are considered to have a common structural motif and, in contact with water, display surface activity and self-assemble into multimolecular aggregates and liquid crystalline phases. Also described are enhanced stability liposomes that incorporate such amphiphilic molecules.SUMMARY OF THE INVENTION

[0003] Described herein are synthetic blood substitutes and methods for making them. More specifically, described herein is a lipid-amphiphile blood-substitute precursor compound having a hydrophobic fatty acid / acyl moiety, a hydrophilic head moiety including a phosphate group, and a pH responsive moiety.

[0004] According to a first aspect of the present invention, there is provided a composition according to claim 1 herein.

[0005] Described is a composition including phospholipid-cholesterol solution, a lipid-amphiphilic precursor compound, hemoglobin, and an allosteric precursor.

[0006] The lipid-amphiphile precursor is configured to self-assemble from a solution mixture of phospholipid and cholesterol in the presence of hemoglobin and an allosteric effector into a hybrid-vesicle resulting from the combined self-assembly of both the amphiphilic lipid-oligomer and the lipids into an advanced vesicular structure containing a hemoglobin / allosteric effector payload. According to a preferred embodiment, the structure is a hybrid vesicle having a diameter of about 80nm to about 300 nm with an outer layer comprising a bilayer of amphiphilic precursor, cholesterol and polyethylene glycol-phosphatidylethanolamine ("PEG-PE") and having a payload comprising hemoglobin, allosteric effector and, optionally, a reducing agent, such as leucomethylene blue, n-benzoyl-leucomethylene blue, or methylene blue. The result is a novel synthetic blood substitute having net negative zeta potential, excellent payload retention and differential gas permeability. Moreover, unlike phospholipid bilayers in liposomal-based HBOCs, the synthetic blood substitute described herein has a tunable membrane (in which different oligomeric amine moieties may be used in the precursor to vary the thickness of the membrane) offering greater integrity due to counter-ionic hemoglobin-precursor interaction and pH responsiveness.

[0007] According to a preferred embodiment, the phospholipids may be PEG 2000 -PE (20 mol %), the ratio of phospholipid to cholesterol is preferably 17.00: 2.34, and the allosteric effector may be RSR-13 (efaproxiral) present in a ratio to hemoglobin of 20:1 to 0.1:1, preferably 10:1:1 to 1: 1, and most preferably 5:1. The lipid-amphiphile-precursor compound may be the compound represented by Formula I:

[0008] According to various alternative embodiments, the pH responsive moiety is preferably an amine, particularly tertiary amines, due to their feasibility to finely tune their pKa and since they can present a marginally lower pKa when substituted with longer hydrophobic chains. Tunable pKa can be achieved based on hydrophobic modification of the amines, whereas, increase of the hydrophobicity of the alkyl substituents will result in the linear decrease of pKa. The high abundance of the positive charges in the self-assembled vesical structure creates a unique charge density that drives the pH shuttle associated with hemoglobin uptake of oxygen at higher pH and the shedding of oxygen at lower pH.

[0009] Examples of suitable pH responsive moieties include chitosan, lysine, ethyleneimine, ester amines, 2-(dimethylamino)ethyl methacrylate, amidoamine, arginine, spermine, spermidine, dimethylethanolamine, urethane, oxylysine, aminoglycolic acid, oxazoline, acrylamide, quaternium-6, piperidine, pyrrolidine, diphenylalanine, 1-adamantyl (5-bromo-2-methoxybenzyl) amine, ornithine, 2-(diisopropylamino)ethyl methacrylate, 4-vinyl pyridine, histidine, β-amino esters.

[0010] According to various other embodiments, the acyl moiety of the lipid amphiphile precursor may constitute the connection between the hydrophobic fatty acid moiety, the hydrophilic head moiety containing the phosphate group and the pH responsive moiety. According to these embodiments, the pH responsive moiety may be linked to, for example, a phosphoglyceride, including phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, lysophosphatidylcholine. The pH responsive moiety may be linked to either the sn1 (more preferred) or sn2 position of a phosphoglyceride. The preferred acyl chain length is 16-18, and the preferred ratio of acyl carbon chain and amine carbon chain would be between 16:4 and 18:6.

[0011] Therefore, the lipid-amphiphile-precursor may have one of the formulas: or a salts or tautomers thereof, wherein: R 1< is a hydrophobic group; R 2< is an amine containing group; and R 3< is chosen from

[0012] According to various embodiments, R 1< is alkyl, and is optionally substituted with one or more R 4< ; where each R 4< is independently chosen from alkyl and halo. According to various preferred embodiments, R 1< is (CH 2 ) 1 CH 3 ; where l is an integer between 10 and 16, inclusive.

[0013] According to various embodiments, R 2< is (CHR 5< ) m R 6< or (CHR 5< ) m NR 7< (CH 2 ) n R 6< ; where each R 5< is independently chosen from H and N(R 7< ) 2 ; at most one R 5< is not H; R 6< is chosen from N(R 8< ) 2 and N=C(NHR 8< ) 2 ; each R 7< is independently chosen from H and alkyl; each R 8< is chosen from H and alkyl; m is an integer between 2 and 6, inclusive; and n is an integer between 2 and 6, inclusive.

[0014] According to various embodiments R 2< is CHR 5< (CH 2 ) o R 6< or CHR 5< (CHR 5< ) o NR7 (CH 2 ) p R 6< ; and each R 5< is independently chosen from H and N(R 7< ) 2 ; at most one R 5< is not H; R 6< is chosen from N(R 8< ) 2 and N=C(NHR 8< ) 2 ; each R 7< is independently chosen from H and alkyl; each R 8< is chosen from H and alkyl; p is an integer between 2 and 6, inclusive; and o is an integer between 1 and 5, inclusive.

[0015] According to various embodiments, R 3< is chosen from

[0016] According to various embodiments, R 3< is

[0017] According to further descriptions, the allosteric effector may be one or more of 2,3-DPG, RSR-13, inositol phosphate, inositol hexaphosphate (IP6), phytic acid, guanosine triphosphate.

[0018] According to still further embodiments, the phospholipid solution is most preferably a mixture of cholesterol and PEG 2000 -PE in a ration of 17.00: 2.34. According to alternative embodiments, the phospholipid solution may be PEG having molecular weights from 500Da to 5000Da in the event a lower or higher membrane thickness of the self-assembled particle is desired.

[0019] According to further embodiments, the synthetic blood substitute may be made by dissolving lipid-oligomeric amphiphile in a solution of phospholipid, followed by evaporation of the phospholipid to form a film. Frozen hemoglobin premixed with allosteric effector is thawed and transferred to the dried film and then mixed. After mixing of hemoglobin payload and membrane components, the mixture is sonicated and then allowed to rest to achieve equilibrium, followed by hydrodynamic diameter measurement of the self-assembled oxygen carrier particle. The mixture is then filtered until outlet flow is clear, and the hydrodynamic diameter is checked again.

[0020] According to further embodiments, following self-assembly of the lipid-amphiphile precursor and hemoglobin into the synthetic blood substitute, the resulting product is lyophilized for packaging. The lyophilized product is a powder comprising amphiphilic precursor, cholesterol and PEG-PE hemoglobin and allosteric effector, optionally also including cryoprotectants.

[0021] Reconstitution at the original EM production concentration (or concentrated) can be achieved with PBS / water by simple mixing and gentle vortexing / agitation.BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 is a schematic representation of the compositions and self-assembly according to an embodiment. Figure 2 is a representation of the synthesis of a precursor designated KC-1003 according to a preferred embodiment. Figure 3 is a schematic representation of the self-assembly of precursor KC-1003 and hb:allosteric effector into an oxygen carrier particle according to a preferred embodiment. Figure 4 is a table showing free hemoglobin detected following purification of batches of oxygen carrier particles using different purification methods. Figure 5 is a chart showing the change in oxygen affinity with changes in pH for oxygen carrier particles. Figure 6 shows the hydrodynamic diameter of a synthetic blood substitute and TEM image (inset) according to an embodiment. Figure 7 shows the electrophoretic potential results according to an embodiment. Figure 8 shows a lyophilized sample of an oxygen carrier particle according to an embodiment. Figure 9 shows various properties of an oxygen carrier particle according to an embodiment before lyophilization, four days after reconstitution, and 14 days after reconstitution. DETAILED DESCRIPTION

[0023] Synthesis of preferred precursor KC-1003 is portrayed in Fig. 2. Lipid-oligomeric amphiphile is preferably synthesized and stored at 4°C. Purity of >90% may be confirmed by qHPLC, 1H NMR, 13C NMR and / or HRMS.Precursor Film Preparation

[0024] 1a. In the test tube (25x250mm) precursor [KC 1003], [80.66 mmol] is dissolved in anhydrous chloroform to a concentration of [8 mg / mL]. Chloroform is transferred by glass syringe or measured by glass cylinder. 1b. [17 mmol] of cholesterol and [2.34 mmol] of [25 mg / mL] [PEG2000-PE] are added to the test tube. Resulting in [100 mM] of surfactant in chloroform. 1c. The test tube is gently swirled for [1 min] to make homogenous / until solution is clear. 1d. Precursor solution is passed through a small bed of cotton to ensure no particulate presence. 1e. Chloroform is evaporated in the test tube under reduced pressure by rotary evaporator. Water bath temp is 50°C. Film is formed on the wall of the test tube and no more liquid chloroform is present. 1f. The test tube is dried in vacuum oven for [12h], HV at room temperature, 20°C. 1g. The test tube is weighed again. Self-Assembly

[0025] 2a. Frozen hemoglobin at is placed at room temperature until melted, 20°C. 2b. Hemoglobin is transferred to 50 mL centrifuge tube by Eppendorf pipette and the lid is sealed immediately. 2c. Hemoglobin is transferred to the dried film in the test tube via micropipette to make a [6.339:1] of precursor to payload components Hb. The vessel is immediately sonicated (described in next step). Note: The same volume of stock Hb soln. to chloroform precursor mass is used. Particle Size Normalization

[0026] 3a. After mixing of payload and membrane components the test tube is immediately probe sonicated for [2 min for <5mL, 5min for >5mL] in ice water. The test tube is swirled by hand on the stationary probe. 3b. After sonication, rest test tube for at least 15-20 min [actual time here] to achieve equilibrium from Brownian motion. 3c. Then, the hydrodynamic diameter is checked by DLS (nm and PDI). Purification

[0027] 4a. After sonication, the contents of the test tube are loaded on the Tangental Flow Filtration System and ran with a 50 nm PS membrane (D02-S05U-05-N) at a rate of 130 mL / min with lactated ringers. 4b. TFF is ran until the flow of outlet was clear by spectrophotometer. 4c. DLS (hydrodynamic diameter and PDI) are again checked and should be within 10% variance.

[0028] The resulting product is lyophilized for packaging. The lyophilized product is a powder comprising amphiphilic precursor, cholesterol and PEG-PE hemoglobin and allosteric effector, optionally also including cryoprotectants. Reconstitution at the original EM production concentration (or concentrated) can be achieved with PBS / water by simple mixing and gentle vortexing / agitation.

Claims

1. A composition comprising: (a) a phospholipid; (b) cholesterol; (c) an oxygen carrier; (d) a lipid-amphiphile precursor having the formula: or a salt or tautomer thereof, wherein: R1 is a hydrophobic group; R2 is chosen from R3 is chosen from and (e) an allosteric effector.

2. A composition according to claim 1, wherein the oxygen carrier is hemoglobin (Hb).

3. A composition according to any one of claims 1 and 2, wherein the allosteric effector is selected from the group consisting of 2,3-DPG, RSR-13, inositol phosphate, inositol hexaphosphate (IP6), phytic acid, and guanosine triphosphate.

4. A composition according to any one of claims 1-3, which self assembles into a vesicle having an amphiphilic lipid bi-layer membrane and a payload comprising said oxygen carrier and said allosteric effector.

5. A composition according to any one of claims 1-4 further comprising a reducing agent; optionally wherein said reducing agent is selected from leucomethylene blue, n-benzoyl-leucomethylene blue, and methylene blue.

6. A composition according to any one of claims 1-5, wherein said composition is lyophilized.

7. A composition according to claim 1, wherein R1 is (CH2)1CH3; and l is an integer between 10 and 16, inclusive, optionally wherein l is 14.

8. A composition according to claim 1, wherein R3 is 9. A composition according to claim 1, wherein R1 is (CH2)14CH3.

10. A method for making a synthetic oxygen carrier, comprising: preparing a composition according to claim 1, allowing said composition to self-assemble into a vesical having a lipid bilayer outer membrane and a payload comprising said oxygen carrier and said allosteric effector; and lyophilizing said self-assembled vesicle; optionally wherein said composition further includes a reducing agent selected from the group consisting of methylene blue, n-benzoyl-leucomethylene blue, and leucomethylene blue.

11. A method for preparing a synthetic oxygen carrier, comprising reconstituting a lyophilized composition according to claim 6.